Clinical Newsletter

    Clinical Newsletter

    Regular updates on our latest clinical studies.

    Subscribe

    Publication search

    Our research and development teams operate at a global level and generate synergies from our collective expertise and by drawing on related disciplines. We are also constantly exchanging information at an international level with independent technical institutions, key opinion leaders and multipliers in order to be able to ensure cooperation and knowledge management of the highest order. As part of this process, we also conduct extensive research, the results of which we continually present in workshops, at conferences and symposiums - either in documentation or talks given by our cooperation partners - and also publish in renowned scientific journals. This database contains a large number of these evidence-based scientific articles, most of which have been evaluated by independent assessors:

    1. Journal article

      The use of Flivasorb® in highly exuding wounds

      British journal of nursing (Mark Allen Publishing) 2009 18(15)

      Exudate can be an excellent indicator of what is happening within a wound and, therefore, provides valuable information during patient assessment. The volume, consistency, and particularly odour and colour, of any exudate will inform the practitioner about bacterial contamination, infection and stage of healing (Hampton and Collins, 2003). However, in the chronic wound, exudate must be effectively managed if the optimal moist environment necessary for wound healing is to be created, the negative effects of chronic exudate on fibroblasts are to be avoided (Phillips et al, 1998), and the surrounding skin protected from the risks of maceration (White, 2006). It is, therefore, important to understand chronic exudate and its effects so that appropriate treatment for the wound and peri-wound area is provided. Flivasorb® (Activa Healthcare) dressings, which include superabsorber particles, can absorb the exudate and retain it firmly within the dressing, ensuring that the potentially damaging chronic wound exudate does not reflect back onto the wound, causing maceration. This article will describe the role of exudates in wound healing, the problems associated with chronic wound exudates and how Flivasorb dressings with superabsorbent particles can provide an optimum healing environment in highly exuding wounds.

      Products Vliwasorb
      Downloads Citation (RIS)
      Further languages
    2. Journal article

      INTÉRET DU PANSEMENT HYDROBALANCE DANS LES PLAIES AIGUES ET CHRONIQUES · EXPÉRIENCE DU SUPRASORB®X

      JOURNAL DES PLAIES ET CICATRISATIONS 2009 68(8) 5658
      Products Suprasorb X
      Downloads Citation (RIS)
    3. Journal article

      Erfahrungsbericht mit einem neuen „Controlled Negative Pressure“-System*

      Wund Management 2009 3(4) 160161
      Products Suprasorb F
      Downloads Citation (RIS)
    4. Journal article

      PROTECTJVE EFFECT OF POLIHEXANIDE ON HACAT KERATINOCYTES IN CO-CULTURE WITH STAPHYLOCOCCUS AUREUS

      Wound Rep Reg 2009 17 84
      Downloads Citation (RIS)
    5. Journal article

      Comparative in vitro study on cytotoxicity, antimicrobial activity, and binding capacity for pathophysiological factors in chronic wounds of alginate and silver-containing alginate

      Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2009 17(4) 511521

      Chronic wounds contain elevated levels of proteases, proinflammatory cytokines, and free radicals. The presence of bacteria further exaggerates the tissue-damaging processes. For successful treatment, the wound dressing needs to manage wound exudates, create a moist environment, inhibit infection, bind pathophysiological factors that are detrimental to wound healing, and provide thermal isolation. Furthermore, it has to relieve pain, be easy to use, show no allergic potency, and not release toxic residues. The present study suggests a comprehensive in vitro approach to enable the assessment of wound dressings to support optimal conditions for wound healing. Three alginate-based wound dressings: alginate alone, alginate containing ionic silver, and alginate with nanocrystalline silver, were tested for biocompatibility, antimicrobial activity, and influence on chronic wound parameters such as elastase, matrix metalloproteases-2, tumor necrosis factor-alpha, interleukin-8, and free radical formation. Alginate was found to bind considerable amounts of elastase, reduce the concentration of proinflammatory cytokines and inhibit the formation of free radicals. Furthermore, alginate showed antibacterial activity and high biocompatibility. Incorporation of silver into alginate fibers increased antimicrobial activity and improved the binding affinity for elastase, matrix metalloproteases-2, and the proinflammatory cytokines tested. Addition of silver also enhanced the antioxidant capacity. However, a distinct negative effect of silver-containing alginates on human HaCaT keratinocytes was noted in vitro.

      PMID 19614916
      Downloads Citation (RIS)
    6. Journal article

      Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers

      Journal of wound care 2009 18(4) 145150

      OBJECTIVE

      To compare the effect on the microcirculation in venous leg ulcers (VLUs) of two treatment regimens that promote a moist wound environment versus paraffin gauze. The hypothesis is that moist wound dressings are more likely to stimulate the microcirculation and therefore angiogenesis.

      METHOD

      Patients with non-healing VLUs were randomised to receive either a foam dressing (Suprasorb P), a collagen dressing (Suprasorb C) plus the foam dressing, or paraffin gauze (control). All patients wore short-stretch high compression bandages. Parameters used to measure the effects of the treatments on the microcirculation were: TcPO2 measurements, video laser Doppler measurements and the number of capillaries in the wound bed. The progression towards healing was measured by the reduction in ulcer area and formation of granulation tissue. The treatment period was four weeks.

      RESULTS

      Significant increases in TcPO2 values were reported between baseline and week 4 for patients receiving the foam dressing only or the collagen plus foam dressing combination (p<0.008 versus p<0.003 respectively). There was also a significant increase in the number of capillaries for the collagen plus foam treatment only (p<0.002).

      CONCLUSION

      This pilot study suggests that a moist wound environment stimulates perfusion of blood and oxygen to the wound tissue, thereby promoting angiogenesis. The collagen and foam dressing combination demonstrated superior results to the control and the foam dressing only. Monitoring the microcirculation may help to assess the effect of dressings on VLU healing, although more research is needed.

      DECLARATION OF INTEREST

      This pilot study was supported by a limited grant from Lohmann & Rauscher GmbH, Germany.

      Products Suprasorb P
      PMID 19349934
      Downloads Citation (RIS)
    7. Journal article

      Anwendungsbeobachtung von einer neuen Form der lokalen Unterdrucktherapie „Suprasorb CNP“

      Wund Management 2009 3(4) 156159
      Downloads Citation (RIS)
    8. Journal article

      Chronic oedema in patients with CVI and ulceration of the lower limb

      British journal of community nursing 2009 14(10) 468

      Patients with chronic venous insufficiency and ulceration can have additional problems with chronic oedema, if a combination of venous and lymphatic insufficiency is present. Standard leg ulcer bandaging systems may not be suitable for reducing chronic oedema. This article provides the opportunity for practitioners to learn more about oedema in patients with CVI and to reflect on their current bandaging practice.

      Products Mollelast
      PMID 19966695
      Downloads Citation (RIS)
    9. Journal article

      NO RESISTANCE AFTER 100 DAYS REPEATED INCUBATION OF STAPHYLOCOCCUS AUREUS WITH POLJHEXANIDE

      Wound Rep Reg 2009 17 84
      Downloads Citation (RIS)
      Further versions
    10. Journal article

      In-vitro-Evaluierung von Polihexanid: biokompatibel und effektiv

      GMS Krankenhaushygiene Interdisziplinaer 2009 4(2)

      Infection may lead to the formation of a chronic wound or is a common complication during their treatment. Rather than relying on just debriding and cleansing the wound, additional therapeutic strategies are commonly applied in an attempt to prevent infection. Therefore, wound dressings combined with antimicrobial agents such as silver, povidine iodine, or polihexanide are increasingly utilized in the treatment of critical colonized or infected chronic wounds. Polihexanide is regarded first choice as therapy option because of its good skin tolerance beside its antimicrobial effects. Furthermore, a positive influence of polihexanide on wound closure was observed in a study with aseptic wounds in piglets. Moreover, polihexanide is able to induce cell proliferation in vitro. In vitro test systems provide valuable tools in the study of substance or material effects on cells. They use highly defined culture conditions and avoid the complex mechanisms which occur in vivo and thus allow the direct measurement of the influence on cell viability and proliferation. For instance, the anti-oxidative effect can be determined and the antimicrobial activity measured in vitro. Furthermore, a co-culture system of HaCaT keratinocytes and Staphylococcus aureus was used to test the capacity of polihexanide to protect the cells from the bacterial damage. Although antiseptics have a lower potency to induce bacterial resistance than antibiotics, concerns have been expressed regarding the overuse of antiseptics and the possible emergence of bacterial adaptation. Hence, an experimental system using microplatelaser-nephelometry was employed to test the adaptation capacity of Staphylococcus aureus during repeated treatment with polihexanide.

      Downloads Citation (RIS)

    This website contains information on products and medical practices which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. Medical practices and regulations can be different from one country to another.